Mar 22 • 31M

Ep. 43 - The hype behind Wegovy

How medical weight loss could alter America's public health

Open in playerListen on);

Appears in this episode

Matthew Handley
Ron Howrigon
The FLATLINING Podcast brings you great healthcare analysis and discussion each week from industry experts who know their way around politics, economics, and a doctors office. Subscribe for more great content and check out the articles at
Episode details

This week on the FLATLINING Podcast, Matthew and Ron discuss the new weight loss drug by Novo Nordisk (NVO 0.00) called Wegovy and how it and similar drugs could change America’s public health. Plus, they talk about why insurance companies aren’t covering it and how and when that could change.


Subscribe to the FLATLINING Podcast on Apple PodcastsSpotify, the iHeartRadio appAmazon MusicGoogle Podcasts, StitcherPandora, TuneIn, and Audible.

Articles mentioned in this program:

Ozempic Can Cause Major Weight Loss. What Happens if You Stop Taking It? - The New York Times

What to Know About Ozempic, Wegovy and the New Weight-Loss Market - CNET

Covering new weight loss drugs could strain Medicare, policy experts warn - STAT News